Apr 15, 2011 by Brian Orelli, PhDShedding the Pounds Through DivestitureGlaxo plans to sell 19 OTC products.
Apr 15, 2011 by Brian Orelli, PhDFewer Needle Pricks for the EuropeansBydureon gets a positive recommendation in Europe.
Apr 15, 2011 by Brian Orelli, PhDDark Clouds Lift Over Pharma DisputeMerck and Johnson & Johnson work out their differences.
Apr 14, 2011 by Brian Orelli, PhDHuman Genome Sciences Will Be Profitable, EventuallySpend now to make money later.
Apr 14, 2011 by Brian Orelli, PhDOne Step Closer to Revenue for DelcathThe worrying isn't over though.
Apr 13, 2011 by Brian Orelli, PhDAbbott’s Potential Billion-Dollar ProblemAbbott's Humira forms antibodies in nearly a quarter of patients.
Apr 13, 2011 by Brian Orelli, PhDDrug Duo Escapes Advisory Panel UnharmedPfizer and Novartis are on their way to expanding their cancer drug indications.
Apr 12, 2011 by Brian Orelli, PhDHow Significant Is 'Statistically Significant' for Biogen?BG-12 could be a blockbuster, but let's wait for the data before applying the crown.
Apr 12, 2011 by Brian Orelli, PhDMerck Joins the Low-Margin PartyYou say emerging markets; I see wasted capital.
Apr 12, 2011 by Brian Orelli, PhDDelcath's Disappointing DelayIs Delcath's delay a sign of poor management?
Apr 11, 2011 by Brian Orelli, PhDClinical Trial Fail? Forget About It.A failure of Medivation and Pfizer's dimebon was expected.
Apr 11, 2011 by Brian Orelli, PhDA Double Dose of Trouble for Big Pharma?Pfizer's Sutent and Novartis's Afinitor head in front of an FDA advisory panel.
Apr 8, 2011 by Brian Orelli, PhDA Shutdown of Binary Events?A government shutdown will likely stop FDA approvals.
Apr 8, 2011 by Brian Orelli, PhDImmunoGen's Hot StartImmunoGen scores some positive data, but were investors expecting less?
Apr 7, 2011 by Brian Orelli, PhDWhen Zombies Attack, Investors WinMore "Thriller" music video than late-night scary movie.
Apr 7, 2011 by Brian Orelli, PhDDrug Approved! But Where's the Name?AstraZeneca prepares to cash in on a minuscule market.
Apr 6, 2011 by Brian Orelli, PhD$1 Billion in Drug Sales Bleeds OutDon't feel too bad for Bayer and J&J, though.
Apr 6, 2011 by Brian Orelli, PhDKilling Bacteria With the Help of a FriendOptimer enlists the services of Cubist.
Apr 6, 2011 by Brian Orelli, PhDMerck Inspired to Eye GrowthA bolt-on acquisition of eye-care specialist Inspire.
